CTOs on the Move


 
SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.syngeninc.com
  • 2125 19th St Suite 120
    Sacramento, CA USA 95818
  • Phone: 916.706.0923

Executives

Name Title Contact Details

Similar Companies

Xeridiem

Xeridiem is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forest Park Medical Center Frisco

Forest Park Medical Center Frisco is a different kind of hospital. We were built on the principle that healthcare doesn’t have to be uncomfortable. Our hospitals are warm and inviting. Our technology pushes the boundaries of what is possible in medical care. Our surgeons and staff are as exceptional as our services. As a full-service, acute-care hospital, Forest Park Medical Center Frisco focuses on providing high quality outcomes to each and every patient who comes through our doors. It’s time to experience medicine the way it should be experienced. Forest Park Medical Center Frisco. Your destination to better health.

Zeltiq Aesthetics Inc

Zeltiq Aesthetics Inc is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

Penn Foundation

Founded in 1955 and located on a 30-acre campus in Sellersville, Pennsylvania, Penn Foundation is a not-for-profit organization providing innovative services that address the mental health, substance use, and intellectual disability needs of our community. Through a broad range of diverse programs that can be tailored to meet individual needs, Penn Foundation provides compassionate, responsive care to more than 10,000 children, adolescents, and adults each year. Our tradition of compassionate care combined with a strong belief in the healing power of hope and the possibility of recovery enables us to help individuals and families grow, develop, and recover to their fullest mental, emotional, and spiritual health.